Search
Bailiantianheng Achieves Primary Endpoint in Phase III Clinical Trial for Nasopharyngeal Cancer with Iza-Bren
1 week ago /
Read about 0 minute
Author：小编
Bailiantianheng has announced that its independently developed, world-first EGFR×HER3 bispecific ADC drug, iza-bren, has successfully met the primary endpoint in the interim analysis of a phase III clinical trial for the treatment of nasopharyngeal cancer. This groundbreaking drug has previously shown promising potential in treating various types of tumors across several clinical trials, and as a result, five indications have been included on the National Medical Products Administration's list of breakthrough therapies.
Bailiantianheng emphasizes its commitment to actively advancing the research and development process of iza-bren and pledges to disclose relevant progress in a timely and transparent manner.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
